RESEARKA

Mechanistically, the preclinical data converge on mTOR inhibition as a modulator of cellular senescence and muscle aging pathways. CorreiaMelo 2019 demonstrated that rapamycin prevents age-related frailty in nfκb1−/− mice without impacting lifespan, suggesting pathway-specific effects on healthspan versus longevity. Translational relevance to humans remains uncertain. mTOR 2026 reported that PI3K/mTOR inhibition attenuates cigarette smoke-induced senescence and the senescence-associated secretory phenotype in oral fibroblasts, implicating a tumor microenvironment remodeling mechanism. Ham 2022 showed distinct and additive effects of calorie restriction and rapamycin in aging skeletal muscle, with the treatment spanning the time of sarcopenic development. The mechanistic substrate underlying these preclinical findings is supported by Impacts 2027, which is investigating how Rapamune affects aged human muscle both functionally and molecularly. These mechanistic human studies and preclinical data collectively suggest that rapamycin's cardiometabolic effects operate through conserved mTOR-dependent pathways.

Citation Support

• source_1 Moel 2025
• source_2 Gkioni 2025
• source_3 Smiaek 2023
• source_4 Willows 2023
• source_5 Harinath 2025